The same cancer cell line can become different experiments
Laboratory versions of the widely used MCF7 breast-cancer cell line differed genetically and in drug response. The finding is a reminder that a cell-line name is not a complete experimental description.
Written retrospectively and published on August 3, 2026.
Background reading, not clinical guidance. This describes published research; it is not a recommendation for any individual case, and the cited studies may have been superseded.
Cancer cell lines are indispensable research tools, but they continue to evolve while laboratories grow, freeze, thaw and passage them. Two flasks labelled with the same cell-line name may share an origin without being genetically identical today.
A 2018 study characterised 27 laboratory strains of MCF7, a widely used breast-cancer cell line. Only 35% of coding point mutations and indels were shared by all 27 strains. Ten chromosome arms differed in at least one comparison.
The divergence changed drug results
When those strains were tested against 321 anticancer compounds, 55 compounds strongly inhibited growth in at least one strain. Of those 55, 48 were completely inactive in at least one other strain. The relevant denominator is the compounds active somewhere, not all compounds tested.
This does not make cell-line research useless. It makes provenance, passage history, authentication, genomic characterisation and replication meaningful parts of the result. Independent work confirms that genetic drift can complicate pharmacogenomic comparisons.
Comments
Threads are public and indexed — please keep personal medical data out of them. Found a clinical error? Open an issue instead.
Comments are not switched on yet — the backend still needs to be configured.